Language：Japanese   Publisher：(一社)日本呼吸器内視鏡学会  

researchmap

Language：Japanese   Publisher：(一社)日本呼吸器内視鏡学会  

researchmap

Language：Japanese   Publisher：(一社)日本呼吸器内視鏡学会  

researchmap

Language：Japanese   Publisher：(一社)日本呼吸器学会  

researchmap

Language：Japanese   Publisher：(一社)日本呼吸器学会  

researchmap

Language：Japanese   Publisher：(一社)日本呼吸器学会  

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

BACKGROUND: The data on bosentan were lacking for the treatment of exercise-induced elevation of pulmonary artery pressure (eePAP) or less severe PH in COPD. This study was conducted to investigate long-term efficacy and safety of bosentan for the treatment of eePAP or less severe PH in COPD. METHODS: COPD patients diagnosed at this hospital as having COPD (WHO functional class II, III or IV) with eePAP or less severe PH whose respiratory symptoms were stable but remained and gradually progressed even after COPD therapy were randomly assigned in a 1:1 ratio to receive either bosentan or no PH treatment for two years and assessed at baseline and every 6 months for respiratory failure, activities of daily living (ADL), lung and heart functions by right heart catheterization (RHC), and other parameters. RESULTS: A total of 29 patients who underwent RHC for detail examination were enrolled in the current study between August 2010 and October 2018.No death occurred in drug-treated group (n = 14) for 2 years; 5 patients died in untreated group (n = 15). Significant differences were noted between the 2 group in hospital-free survival (686.00 ± 55.87 days vs. 499.94 ± 53.27 days; hazard ratio [HR], 0.18; P = 0.026) and overall survival (727 days vs. 516.36 ± 55.38 days; HR, 0.095; P = 0.030) in all causes of death analysis, but not in overall survival in analysis of respiratory-related death. Bosentan was not associated with increased adverse events including requiring O2 inhalation. CONCLUSIONS: This study suggested that the prognosis for COPD patients with eePAP or less severe PH presenting with respiratory symptoms was very poor and that bosentan tended to improve their prognosis and suppress ADL deterioration without worsening respiratory failure. TRIAL REGISTRATION: This study was registered with UMIN-CTR Clinical Trial as UMIN000004749 . First trial registration at 18/12/2010.

DOI： 10.1186/s12890-024-02895-0

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

A 69-year-old woman was diagnosed with idiopathic interstitial pneumonia (IIP). The patient underwent a combination therapy of steroid therapy and intravenous cyclophosphamide, long-term oxygen therapy, and the initiation of Nintedanib. However, there was no improvement in IIP, and as a result, the activities of daily living also declined. As one of the various examinations conducted, the results of the right heart catheterization diagnosed the patient with mild pulmonary hypertension, and Macitentan therapy was initiated. The subsequent clinical course appeared to show an improvement in Idiopathic Interstitial Pneumonia (IIP) by adding Macitentan therapy to Nintedanib therapy.

DOI： 10.1016/j.rmcr.2024.102058

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

Abemaciclib, a cyclin-dependent kinase 4/6 inhibitor, is crucial in treating hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic or recurrent breast cancer. However, its association with drug-induced interstitial lung disease (DI-ILD) is concerning. We present an 82-year-old woman with breast cancer receiving abemaciclib, who developed persistent cough and malaise. Initial diagnostics suggested pneumonia, supported by ground-glass opacities and consolidations on chest high-resolution computed tomography. Suspecting DI-ILD, a transbronchial lung cryobiopsy (TBLC) was performed, revealing fibrosing organizing pneumonia and confirming abemaciclib-induced ILD. Discontinuing abemaciclib led to significant symptom improvement, supporting the diagnosis. This case report describes the clinical presentation and diagnostic approach in a patient with suspected abemaciclib-induced ILD, including the use. To our knowledge, this is the first reported case of fibrosing organizing pneumonia as a histopathological pattern in abemaciclib-induced ILD, expanding knowledge of this therapy's pulmonary adverse events. Histopathological features included diffuse lymphocytic infiltration, polypoid intra-alveolar fibrosis, intraluminal granulation tissue plugs with dense hyalinization, hyalinized fibrotic alveolar septa lesions, and obliterative fibrotic processes affecting alveolar ducts. Our case suggests that TBLC might be useful in recognizing DI-ILD by providing detailed lung tissue examination, which can facilitate early diagnosis and guide management. Identifying fibrosing organizing pneumonia indicated a potentially corticosteroid-responsive pathology, suggesting a more favorable prognosis compared with patterns like diffuse alveolar damage. This case highlights the potential for abemaciclib-induced ILD to occur even after prolonged treatment periods, emphasizing the importance of vigilance and consideration of diagnostic intervention for patients on cyclin-dependent kinase 4/6 inhibitors presenting with respiratory symptoms. Timely recognition and appropriate management may mitigate adverse outcomes. Further studies are needed to confirm these findings and to better understand the role of TBLC and histopathological examination in diagnosing and managing abemaciclib-induced ILD.

DOI： 10.1177/11782234241301314

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

A female patient developed multiple intestinal perforations at 31 and 43 years of age. Because of her family history of pneumothorax and intestinal perforation, Ehlers-Danlos syndrome (EDS) was suspected when she visited our hospital at 52 years. She was diagnosed with vascular Ehlers-Danlos syndrome (vEDS) and developed bilateral external iliac artery dissection. A CT scan at the time of admission revealed granular and infiltrative shadows in both lungs with bronchiectasis. The patient was also diagnosed with Mycobacterium avium complex (MAC) pulmonary disease, and drug susceptibility to clarithromycin was confirmed. After treatments with rifampicin, ethambutol, and clarithromycin were started, the acid-fast bacilli cultures taken from sputum were negative, and respiratory symptoms partially improved after about 1 month. vEDS is reportedly associated with lung diseases, such as pneumothorax and cystic lung lesions, but there are few reports of respiratory infections with vEDS. Moreover, there are no reports of complications associated with MAC disease. We report a case of vEDS with rare complications and suggest the possible mechanism of infection.

DOI： 10.1016/j.rmcr.2024.102119

PubMed

researchmap

Language：Japanese   Publisher：(一社)日本呼吸器内視鏡学会  

researchmap

Language：Japanese   Publisher：(一社)日本呼吸器学会  

researchmap

Language：Japanese   Publisher：(一社)日本呼吸器学会  

researchmap

Language：Japanese   Publisher：(一社)日本呼吸器学会  

researchmap

Language：Japanese   Publisher：(NPO)日本呼吸器内視鏡学会  

researchmap

Language：Japanese   Publisher：(一社)日本呼吸器学会  

researchmap

Language：Japanese   Publisher：(一社)日本呼吸器内視鏡学会  

researchmap

Language：Japanese   Publisher：日本結核・非結核性抗酸菌症学会関東支部学会・日本呼吸器学会関東地方会  

researchmap

Language：Japanese   Publisher：(NPO)日本呼吸器内視鏡学会  

researchmap

Language：Japanese   Publisher：(一社)日本呼吸器内視鏡学会  

researchmap

Language：Japanese   Publisher：日本結核・非結核性抗酸菌症学会関東支部学会・日本呼吸器学会関東地方会  

researchmap

Language：Japanese   Publisher：(一社)日本呼吸器内視鏡学会  

researchmap

Language：Japanese   Publisher：日本結核・非結核性抗酸菌症学会関東支部学会・日本呼吸器学会関東地方会  

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

Some of the most common causes of chronic cough include cough variant asthma (CVA), bronchial asthma (BA), and asthma-COPD overlap (ACO). Although there is some overlap in the etiology of these diseases, it is clinically important to attempt an early differential diagnosis due to treatment strategies and prognoses. Spirometry and impulse oscillometry (IOS) before and after bronchodilator inhalation were analyzed for clinically diagnosed CVA (cCVA, n = 203), BA (cBA, n = 222), and ACO (cACO, n = 61).A significant difference in ΔFEV1 was observed between cBA and cCVA (ΔFEV1 improvement of 122.5 mL/5.4% and 65.7mL/2.2%, respectively), but no difference was observed in ΔPEF, ΔV50, or ΔV25. Except for R20 (resistance at 20 Hz), significant differences between the three groups were observed in IOS. In IOS, cCVA and cBA showed comparable peripheral airway response to bronchodilator which was thought to be commensurate with changes in V50 and V25. cACO improved ΔFEV1 improvement of 81.0 mL/6.2% and was distinguished by a downward Xrs (respiratory system reactance) waveform with a limited bronchodilator response. FEV1/FVC, %FEV1, and %V25 had relatively strong correlations with the three IOS parameters, X5 (reactance at 5 Hz), Fres (resonant frequency), and ALX (low-frequency reactance area), in the correlation between IOS and spirometers.Changes in IOS parameters were more sensitive in this study than changes in FEV1 or the flow-volume curve. Considering the benefits and relevance of the two different tests, simultaneous IOS and spirometry testing were useful in the diagnosis of asthmatic cough.

DOI： 10.1080/02770903.2022.2094803

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

Following COVID-19 vaccination, ipsilateral axillary and cervical lymphadenopathy may occur, called vaccine-related hypermetabolic lymphadenopathy, which is considered reactive lymphadenopathy. We report here a case of Kikuchi-Fujimoto disease, which occurred three months after vaccination with COVID-19 vaccine. The patient had cervical and axillary lymph node enlargement and a short-term fever that resolved spontaneously after the first and second vaccines. On the 90th day after the first vaccination, the patient developed a high fever and pathologically diagnosed necrotizing lymphadenitis in the axilla, which was diagnosed as Kikuchi-Fujimoto disease. Gallium scintigraphy showed localized swelling and strong uptake in the ipsilateral axilla. It implies the possibility of Kikuchi-Fujimoto Disease in axillary drainage lymph nodes in association with COVID-19 vaccine. Although only a few cases have been reported so far, this case is novel because of its later onset and diagnosis based on pathological and gallium scintigraphy imaging findings.

DOI： 10.1080/21645515.2022.2071080

PubMed

researchmap

Language：Japanese   Publisher：(一社)日本呼吸器内視鏡学会  

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

BACKGROUND: Although corticosteroids are expected to be a candidate therapy for coronavirus disease 2019 (COVID-19) through the suppression of cytokine production, the efficacy in non-severe patients who do not require supplemental oxygen remains controversial. The aim of this study was to investigate the efficacy of corticosteroid therapy for non-severe patients. METHODS: We performed a retrospective observational study for 10 patients with non-severe COVID-19 who received corticosteroid therapy at our institute between July 1, 2020, and January 31, 2021. RESULTS: The median age of the 10 patients was 60 years, and nine patients were male. Nine of the 10 patients had multiple comorbid conditions (e.g., hypertension, diabetes and obesity). Although blood oxygen saturation was maintained above 95%, all patients showed persistent fever and deterioration of their chest imaging findings. Thus, we decided to initiate corticosteroid treatment. The median duration from the onset of symptoms to the initiation of corticosteroid therapy was eight days. All patients used dexamethasone (6 mg/day) as corticosteroid therapy, and the median period was 7.5 days. After the start of corticosteroid therapy, all patients showed a rapid clinical improvement, and no patients showed severe progression. CONCLUSION: The latest World Health Organization guidance recommends against corticosteroid treatment for non-severe patients. In this report, we showed that the early administration of corticosteroids during the non-critical phase, when oxygen supplementation is not required, was useful for the early improvement and prevention of severe disease in patients with risk factors for severe COVID-19 and worsening clinical symptoms.

DOI： 10.1272/jnms.JNMS.2022_89-409

PubMed

researchmap

Language：Japanese   Publisher：(一社)日本呼吸器学会  

researchmap

Language：Japanese   Publisher：(一社)日本呼吸器学会  

researchmap

Language：Japanese   Publisher：(一社)日本呼吸器学会  

researchmap

Language：Japanese   Publisher：(一社)日本呼吸器学会  

researchmap

Language：Japanese   Publisher：(一社)日本呼吸器学会  

researchmap

Language：Japanese   Publisher：(一社)日本呼吸器学会  

researchmap

Language：Japanese   Publisher：(一社)日本呼吸器学会  

researchmap

Language：Japanese   Publisher：日本結核・非結核性抗酸菌症学会関東支部学会・日本呼吸器学会関東地方会  

researchmap

Language：Japanese   Publisher：日本結核・非結核性抗酸菌症学会関東支部学会・日本呼吸器学会関東地方会  

researchmap

Language：Japanese   Publisher：(NPO)日本呼吸器内視鏡学会  

researchmap

Language：Japanese   Publisher：(NPO)日本呼吸器内視鏡学会  

researchmap

Language：Japanese   Publisher：日本内科学会-関東地方会  

researchmap

Language：Japanese   Publisher：日本内科学会-関東地方会  

researchmap

Language：English   Publishing type：Research paper (scientific journal)   Publisher：CUREUS  

Background The role of inhaled corticosteroid (ICS) in chronic obstructive pulmonary disease (COPD) is unclear. Hence, this study aimed to evaluate the efficacy of ICS as an add-on to long-acting muscarinic antagonist (LAMA)/long-acting beta 2 agonist (LABA), which was assessed using the impulse oscillation system (IOS), in patients with COPD. Methodology We included patients with COPD whose treatment was changed from LAMA/LABA (≥four weeks) to ICS/LAMA/LABA between April 2019 and March 2021. To gain insight into the effect and safety of ICS-containing triple therapy for COPD, pulmonary function; Short-Form 36, St. George's Respiratory Questionnaire, COPD Assessment Test, and modified Medical Research Council scores; and airway resistance assessed using the IOS from one week before LAMA/LABA was switched to ICS/LAMA/LABA therapy until more than eight but less than twelve weeks after switching were evaluated. Results In total, 46 patients with COPD (mean age: 72.28 ± 7.81 years) were included in the study. None of the pulmonary function test parameters significantly changed from baseline values (mean difference in forced expiratory volume in one second [FEV1.0]: +0.032, P = 0.12; percentage FEV1.0 [FEV1.0%]/forced vital capacity [FVC]: -0.58, P = 0.42; and FVC: +0.087, P = 0.058). Meanwhile, the IOS showed that resonant frequency (mean difference from baseline: -2.12, P < 0.0001) and bodily pain scores in the St. George's Respiratory Questionnaire (mean difference: -7.03, P = 0.031) significantly decreased. Conclusions Switching from LAMA/LABA to ICS/LAMA/LABA therapy reduces airway elasticity-to-inertial resistance ratios, which may lead to structural airway improvements in patients with COPD.

DOI： 10.7759/cureus.19168

PubMed

researchmap

Language：Japanese   Publisher：日本医科大学医学会  

researchmap

Language：Japanese   Publisher：日本結核・非結核性抗酸菌症学会関東支部学会・日本呼吸器学会関東地方会  

researchmap

Language：Japanese   Publisher：(NPO)日本呼吸器内視鏡学会  

researchmap

Language：Japanese   Publisher：(NPO)日本呼吸器内視鏡学会  

researchmap

Language：Japanese   Publisher：(一社)日本呼吸器学会  

researchmap

Language：Japanese   Publisher：(一社)日本呼吸器学会  

researchmap

Language：Japanese   Publisher：(一社)日本呼吸器学会  

researchmap

Language：Japanese   Publisher：(一社)日本呼吸器学会  

researchmap

Language：Japanese   Publisher：(一社)日本呼吸器学会  

researchmap

Language：Japanese   Publisher：(一社)日本呼吸器学会  

researchmap

Language：Japanese   Publisher：(一社)日本呼吸器学会  

researchmap

Language：Japanese   Publisher：(一社)日本呼吸器学会  

researchmap

Language：Japanese   Publisher：(一社)日本呼吸器学会  

researchmap

Language：Japanese   Publisher：(一社)日本呼吸器学会  

researchmap

Language：Japanese   Publisher：(一社)日本呼吸器学会  

researchmap

Language：Japanese   Publisher：(一社)日本呼吸器学会  

researchmap

Language：Japanese   Publisher：(一社)日本呼吸器学会  

researchmap

Language：Japanese   Publisher：(一社)日本呼吸器学会  

researchmap

Language：Japanese   Publisher：(一社)日本呼吸器学会  

researchmap

Language：Japanese   Publisher：(NPO)日本呼吸器内視鏡学会  

researchmap

Language：Japanese   Publisher：(NPO)日本呼吸器内視鏡学会  

researchmap

Language：Japanese   Publisher：(NPO)日本呼吸器内視鏡学会  

researchmap

Language：Japanese   Publisher：(NPO)日本呼吸器内視鏡学会  

researchmap

Language：Japanese   Publisher：(NPO)日本呼吸器内視鏡学会  

researchmap

Language：Japanese   Publisher：日本結核・非結核性抗酸菌症学会関東支部学会・日本呼吸器学会関東地方会  

researchmap

Language：Japanese   Publisher：(NPO)日本呼吸器内視鏡学会  

researchmap

Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)  

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

We report a case of non-small-cell lung cancer (NSCLC) to small-cell lung cancer (SCLC) transformation after epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) treatment. The patient was a man who diagnosed with EGFR-mutant advanced NSCLC. After he was introduced afatinib, his tumor had been reduced by the treatment. However, plasma pro-gastrin-releasing peptide (ProGRP) became higher with disease progression, and SCLC was detected at the second biopsy. It is suggested that elevation of plasma ProGRP level before EGFR-TKI therapy is useful for predicting EGFR-mutant NSCLC to SCLC transformation.

DOI： 10.1016/j.rmcr.2019.100837

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

researchmap

Language：Japanese   Publisher：(一社)日本呼吸器内視鏡学会  

researchmap

Language：Japanese   Publisher：(一社)日本呼吸器内視鏡学会  

researchmap

Language：Japanese   Publisher：(NPO)日本肺癌学会  

researchmap

Language：English   Publishing type：Research paper (scientific journal)   Publisher：BIOMED CENTRAL LTD  

Background: No drugs have been approved for the treatment of patients with pulmonary hypertension (PH) secondary to idiopathic pulmonary fibrosis (IPF), particularly those with idiopathic honeycomb lung. This study was conducted to investigate the long-term efficacy and safety of bosentan for PH based on changes in prognosis and respiratory failure.
Methods: IPF patients with borderline or less severe PH and completely organized honeycomb lung were randomized (1:1) to bosentan or no treatment for PH for 2 years and assessed at baseline and every 6 months for respiratory failure, activities of daily living (ADL), lung and heart functions by right cardiac catheterization, and other parameters. An interim analysis was performed, however, following detection of a significant survival benefit favoring bosentan therapy.
Results: Significant differences were noted for the bosentan-treated (n = 12) vs. untreated (n = 12) groups in hospital-free survival (603.44 +/- 50.074 days vs. 358.87 +/- 68.65 days; hazard ratio [HR], 0.19; P = 0.017) and overall survival (671 days vs. 433.78 +/- 66.98 days; HR, 0.10; P = 0.0082). Again, significant improvements were noted for the bosentan-treated group from baseline to month 6 or 12 in several indices in ADL, pulmonary circulation, and %DLCO. Without requiring O-2 inhalation, bosentan was associated with no increase but a trend toward a decrease in adverse events and an improvement in respiratory status.
Conclusions: Bosentan tended to improve prognosis and ADL without worsening respiratory failure in IPF patients with borderline or less severe PH and completely organized honeycomb lung alone.

DOI： 10.1186/s12890-017-0523-2

Web of Science

researchmap

Language：English   Publishing type：Research paper (scientific journal)   Publisher：W.B. Saunders Ltd  

A 72-year-old woman was admitted to our hospital and was diagnosed with interstitial pneumonia (IP) associated with amyopathic dermatomyositis (ADM). The patient experienced three acute IP exacerbations in the 7 years that followed, which were each treated and resolved with steroid pulse therapy. The patient was closely examined for respiratory failure with right heart catheterization (RHC), which demonstrated that she had a mean pulmonary artery pressure (mPAP) of 34 mmHg. The patient was thus diagnosed as having pulmonary hypertension (PH) associated with anti-synthetase syndrome (ASS) and was started on bosentan therapy, which led to improvements in mPAP as well as in subjective symptoms over time. Indeed, she had had no acute exacerbations with serum markers of IP remaining low over 6 years following initiation of bosentan therapy, suggesting that bosentan may have a role in controlling IP. In addition, she was confirmed to be anti-ARS antibody-positive after 5 years of bosentan therapy, when anti-aminoacyl tRNA synthetase (anti-ARS) antibody testing became available.

DOI： 10.1016/j.rmcr.2017.03.021

Scopus

researchmap

Language：English   Publisher：WILEY-BLACKWELL  

Web of Science

researchmap

Language：Japanese   Publisher：(NPO)日本肺癌学会  

researchmap

Language：Japanese   Publisher：(NPO)日本肺癌学会  

researchmap

Language：Japanese   Publisher：特定非営利活動法人 日本呼吸器内視鏡学会  

DOI： 10.18907/jjsre.37.Special_S282_2

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

researchmap

Language：English   Publishing type：Research paper (scientific journal)   Publisher：WILEY-BLACKWELL  

Introduction
Some complications of obstructive sleep-disordered breathing (OSDB), such as heart failure including right ventricular (RV) overload, are more serious than an increase of the apnea-hypopnea index (AHI) or respiratory disturbance index (RDI). These serious complications may contribute to the worsening of OSDB.
Objective
To explore the relationship between RV function in OSDB patients while awake and the severity of OSDB.
Methods
Fifty-eight patients were evaluated to determine the cause of OSDB and were subjected to various examinations, including cardiac ultrasonography. Of them, 54 were included in this analysis.
Results
Isovolumetric relaxation time decreased as AHI increased to about 40 events/h and increased when AHI increased beyond 40 events/h. The total ejection isovolume index increased as AHI increased to approximately 35 events/h and decreased when AHI increased beyond 35 events/h.
Conclusions
RV function gradually deteriorated from the early stages of obstructive sleep apnea syndrome, even though there was no apparent increase in pulmonary artery pressure. The results of this study indicated that the progression of OSDB correlated with RV function determined in patients while awake. Further studies are required to clarify this relationship, including assessment of components of RV function.

DOI： 10.1111/crj.12051

Web of Science

researchmap

Language：Japanese   Publishing type：Research paper (scientific journal)   Publisher：株式会社 新興医学出版社  

researchmap

Language：English   Publishing type：Research paper (scientific journal)   Publisher：WILEY-BLACKWELL  

Background and objective: Systemic effects of COPD include skeletal muscle dysfunction; the lactate threshold (LT) is an index of such dysfunction. However, it is not feasible in daily clinical practice to accurately determine the LT in all patients with COPD. There is no simple, practical and non-invasive index for determining the time at which rehabilitation should start. Previous studies have shown that the LT corresponds to the point at which the blood lactate concentration is 0.5 mmol/L above baseline (LT Delta 0.5 mmol/L). The aim of the study was to assess the value of LT Delta 0.5 mmol/L as an index of selecting candidates for pulmonary rehabilitation in COPD patients.
Methods: Eighteen male outpatients with COPD were enrolled. Exercise tolerance based on the 12-min walk test and treadmill exercise test, lactate concentrations and activities of daily living before and after individual exercise stress testing were assessed.
Results: There were no significant differences in the 12-min walk distance or metabolic equivalents between patients with and without a 0.5 mmol/L or more increase in lactate from baseline to post-walk test. However, significant differences were observed in activities of daily living, as assessed using Fletcher&apos;s scale, between those with and without a 0.5 mmol/L or greater increase in lactate from baseline to post-walk test.
Conclusions: In daily clinical practice, a 0.5 mmol/L or greater increase in lactate from baseline to post-12-min walk test may be utilized as an index to determine when COPD patients should start rehabilitation, or to assess muscle alterations in the lower extremities in COPD patients undergoing rehabilitation.

DOI： 10.1111/j.1440-1843.2008.01295.x

Web of Science

researchmap

Language：English   Publishing type：Research paper (scientific journal)   Publisher：HUMANA PRESS INC  

Objective We conducted a phase I study of paclitaxel (PTX), carboplatin (CBDCA), and UFT in chemo-naive patients with advanced non-small cell lung cancer (NSCLC). Method Twenty-one chemo-naive patients with advanced NSCLC were enrolled. The study was conducted as a phase I dose-escalation study of various doses of systemic PTX followed by CBDCA on day I and oral UFT (400 mg/m(2)) on days 1-5 and 8-12, with the cycle repeated at 21 -day intervals. At least three patients were enrolled in each step. Results The main toxicities were neutropenia and paresthesia, but were tolerable and reversible in all cases. Overall response rate was 57% (12 out of 21). The MTD was not reached at the highest dose level after the first cycle. Given previous recommends of PTX at 225 mg/m(2) and CBDCA AUC 6 for two-drug therapy, the recommended dose for the phase 11 study under our regimen was set at PTX 225 mg/m(2) on day 1, CBDCA AUC 6 on day 1, and UFF 400 mg/m(2) on days 1-5 and 8-12. Conclusion The combination of PTX, CBDCA, and UFT showed promising activity and acceptable toxicity in these chemo-naive patients, supporting the development of this combination as a feasible chemotherapeutic option for advanced NSCLC.

DOI： 10.1007/s12032-007-0027-7

Web of Science

researchmap

Language：Japanese   Publisher：特定非営利活動法人 日本呼吸器内視鏡学会  

78歳女性, 肺異常影精査目的より気管支鏡施行中に胸痛出現, ショックとなる. 完全房室ブロック, II, III, aVF, V1〜3誘導でST上昇, 心エコーで広範に壁運動低下. 一時的心臓ペーシング, IABP補助下に冠動脈造影施行. 右冠動脈に大量血栓を認め, 血栓吸引を行った. しかし血圧回復せず, PCPSを開始しICU入室. 入室後徐々に血圧が回復, 壁運動も著明に改善し, 第3病日にPCPS, 第4病日にIABPから離脱できた. 病理診断は肺腺癌であった. この症例から気管支鏡の合併症としての心筋梗塞につき文献を含め考察する.

DOI： 10.18907/jjsre.27.5_422_5

researchmap

Language：Japanese   Publishing type：Research paper (scientific journal)  

researchmap

Language：English   Publishing type：Research paper (scientific journal)   Publisher：Springer Japan  

Our aim was to evaluate the effects of eradication and the incidence of secondary resistance by long-term low-dose daily 14-membered-ring macrolide therapy on Helicobacter pylori (H. pylori) infection in patients with chronic lower respiratory tract inflammatory disease. In a retrospective analysis, we studied the seroprevalence of H. pylori IgG in 90 patients with inflammation of the lower respiratory tract (68 had been treated with macrolide and 22 served as controls). Then, in a prospective analysis, we evaluated the eradication effect of macrolide therapy by the decline of IgG values and the 13C-urea breath test. Only long-term macrolide use significantly affected the seroprevalence of H. pylori IgG. However, macrolide therapy did not reduce the H. pylori IgG values in 24 patients and did not eradicate H. pylori in 13C-urea breath tests. Chemosensitivity testing was performed on three H. pylori strains obtained by gastric biopsy from patients in whom the disease could not be eradicated. Only one strain demonstrated a resistant character. Daily long-term low-dose 14-membered-ring macrolide therapy for patients with lower respiratory inflammatory disease may not be sufficient to eradicate H. pylori, but some strains do not acquire a resistant nature.

DOI： 10.1007/s10156-004-0308-4

Scopus

PubMed

researchmap

Language：Japanese   Publishing type：Research paper (scientific journal)  

researchmap

Language：Japanese   Publisher：(一社)日本呼吸器学会  

researchmap

Language：Japanese   Publisher：(一社)日本呼吸器学会  

researchmap

Language：Japanese   Publishing type：Research paper (scientific journal)   Publisher：JAPANESE SOCIETY FOR TUBERCULOSIS  

In 1998, Prevention Committee of the Japanese Society for Tuberculosis announced guidelines for dealing with nosocomial tuberculosis infections. These guidelines recommended the two-step tuberculin tests (TST) as baseline data for each medical employee when they started to work. If accurate records of previous TSTs are available in addition to baseline data, they are useful to evaluate the presence of tuberculosis infection when they started to work. We therefore studied the frequency profile of size of TST among medical employees in INBA-HITEC Medical Center and discussed methods to improve investigative measures for tuberculosis infection, and prior to skin testing we asked self-reporting questionnaires regarding history of previous BCG vaccinations and TSTs. We expected that their records of previous TSTs were accurately preserved, however, records of previous TSTs reported by medical employees were found to be inaccurate. From two-step TSTs results, the magnitude of booster phenomenon was defined by diameter of erythema and induration. Results demonstrated that the increase of induration size was larger in subjects ≥41-years-old than in subjects <41-years-old. Regarding booster phenomenon, no statistically significant differences were detected according to type of duty post. Many subjects with size of TST erythema ≥30 mm on the first test showed increase erythema ≥10 mm on the second test. We therefore suggest that the second test be made for those showing reaction size ≥30 mm on the first test.

DOI： 10.11400/kekkaku1923.77.347

CiNii Books

researchmap

Other Link： https://jlc.jst.go.jp/DN/JALC/00153546226?from=CiNii

Language：Japanese   Publisher：特定非営利活動法人 日本呼吸器内視鏡学会  

DOI： 10.18907/jjsre.24.5_416_4

researchmap

Language：Japanese   Publishing type：Research paper (scientific journal)  

CiNii Books

researchmap

Other Link： http://search.jamas.or.jp/link/ui/2002054778

Language：Japanese   Publishing type：Research paper (scientific journal)   Publisher：The Japan Society for Respiratory Endoscopy  

Seventeen, mechanically ventilated acute respiratory failure patients with diffuse pulmonary shadows were studied. The diagnostic efficacy and safety of bronchioloalveolar lavage(BAL) were examined for these early stage severe respiratory failure patients. Our results showed that BAL could be performed extremely safely in patients with severe respiratory failure. Weaning from mechanical ventilation was successful in 8 patients(47.2%). The most important predictive factor for weaning was the percentile of eosinophils in BAL fluids.

DOI： 10.18907/jjsre.23.1_11

CiNii Books

researchmap

Language：Japanese   Publisher：一般社団法人 日本アレルギー学会  

DOI： 10.15036/arerugi.50.936_1

researchmap

Language：Japanese   Publisher：特定非営利活動法人 日本呼吸器内視鏡学会  

DOI： 10.18907/jjsre.22.2_144_3

researchmap

Language：Japanese   Publisher：一般社団法人 日本アレルギー学会  

DOI： 10.15036/arerugi.49.235_4

researchmap

Language：Japanese   Publishing type：Research paper (scientific journal)  

CiNii Books

researchmap

Language：Japanese   Publishing type：Research paper (scientific journal)  

researchmap

Language：Japanese   Publishing type：Research paper (scientific journal)  

CiNii Books

researchmap

Language：Japanese   Publishing type：Research paper (scientific journal)  

researchmap

J-GLOBAL

researchmap

Language：Japanese   Publisher：(NPO)日本呼吸器内視鏡学会  

researchmap

Language：English   Publishing type：Research paper, summary (international conference)   Publisher：WILEY  

Web of Science

researchmap

Language：English   Publishing type：Research paper, summary (international conference)   Publisher：WILEY  

Web of Science

researchmap

Language：English   Publishing type：Research paper, summary (international conference)   Publisher：WILEY  

Web of Science

researchmap

Language：Japanese   Publisher：(NPO)日本肺癌学会  

researchmap

Language：English   Publishing type：Research paper, summary (international conference)   Publisher：WILEY-BLACKWELL  

Web of Science

researchmap

Language：English   Publishing type：Research paper, summary (international conference)   Publisher：WILEY-BLACKWELL  

Web of Science

researchmap

Language：English   Publishing type：Research paper, summary (international conference)   Publisher：WILEY-BLACKWELL  

Web of Science

researchmap

Language：English   Publishing type：Research paper, summary (international conference)   Publisher：WILEY-BLACKWELL  

Web of Science

researchmap

Language：English   Publishing type：Research paper, summary (international conference)   Publisher：WILEY-BLACKWELL  

Web of Science

researchmap

Language：English   Publishing type：Research paper, summary (international conference)   Publisher：WILEY-BLACKWELL  

Web of Science

researchmap

Language：English   Publishing type：Research paper, summary (international conference)   Publisher：WILEY-BLACKWELL  

Web of Science

researchmap

Language：English   Publishing type：Research paper, summary (international conference)   Publisher：WILEY-BLACKWELL  

Web of Science

researchmap

Language：English   Publishing type：Research paper, summary (international conference)   Publisher：WILEY-BLACKWELL  

Web of Science

researchmap

Language：English   Publishing type：Research paper, summary (international conference)   Publisher：WILEY-BLACKWELL  

Web of Science

researchmap

Language：English   Publishing type：Research paper, summary (international conference)   Publisher：WILEY-BLACKWELL  

Web of Science

researchmap

Language：Japanese   Publisher：(NPO)日本肺癌学会  

researchmap

Language：Japanese   Publisher：(NPO)日本肺癌学会  

researchmap

Language：Japanese   Publisher：(NPO)日本呼吸器内視鏡学会  

DOI： 10.18907/jjsre.27.5_421_2

researchmap

Language：Japanese   Publisher：(NPO)日本肺癌学会  

researchmap

Language：Japanese   Publisher：日本医科大学医学会  

researchmap

Language：Japanese   Publisher：日本肺癌学会  

researchmap

Language：Japanese   Publisher：日本肺癌学会  

CiNii Books

researchmap

Language：Japanese   Publisher：日本肺癌学会  

CiNii Books

researchmap

Language：Japanese   Presentation type：Oral presentation (general)  

researchmap

Language：English   Presentation type：Poster presentation  

researchmap

Language：English   Presentation type：Poster presentation  

Venue：Hanoi, Vietnam  

researchmap

Language：English   Presentation type：Poster presentation  

researchmap

Language：English   Presentation type：Poster presentation  

Venue：Kyoto, Japan  

researchmap

Language：English   Presentation type：Poster presentation  

Venue：Kyoto, Japan  

researchmap

Language：English   Presentation type：Poster presentation  

Venue：Kyoto, Japan  

researchmap

Language：English   Presentation type：Poster presentation  

Venue：Kyoto, Japan  

researchmap

Language：Japanese   Presentation type：Oral presentation (general)  

researchmap

Language：Japanese   Presentation type：Oral presentation (general)  

researchmap

Language：Japanese   Presentation type：Oral presentation (general)  

researchmap

Language：Japanese   Presentation type：Oral presentation (general)  

researchmap

Language：Japanese  

researchmap

Language：Japanese   Presentation type：Oral presentation (general)  

researchmap

Language：Japanese   Presentation type：Oral presentation (general)  

researchmap

Language：Japanese   Presentation type：Oral presentation (general)  

researchmap

Language：Japanese   Presentation type：Oral presentation (general)  

researchmap

Language：Japanese   Presentation type：Oral presentation (general)  

researchmap

Language：Japanese   Presentation type：Oral presentation (general)  

researchmap

Language：Japanese   Presentation type：Oral presentation (general)  

researchmap

Language：Japanese   Presentation type：Oral presentation (general)  

researchmap

Language：Japanese   Presentation type：Oral presentation (general)  

researchmap

Language：Japanese   Presentation type：Oral presentation (general)  

researchmap

Language：Japanese   Presentation type：Oral presentation (general)  

researchmap

Language：Japanese   Presentation type：Oral presentation (general)  

researchmap

Language：Japanese   Presentation type：Oral presentation (general)  

researchmap

Language：Japanese   Presentation type：Oral presentation (general)  

researchmap

Language：Japanese   Presentation type：Symposium, workshop panel (nominated)  

researchmap

Language：Japanese   Presentation type：Symposium, workshop panel (public)  

researchmap

Language：English   Presentation type：Poster presentation  

Venue：Bangkok,Thailand  

researchmap

Language：English   Presentation type：Poster presentation  

Venue：Bangkok,Thailand  

researchmap

Language：English   Presentation type：Poster presentation  

Venue：Bangkok,Thailand  

researchmap

Language：Japanese   Presentation type：Oral presentation (general)  

researchmap

Language：Japanese   Presentation type：Oral presentation (general)  

Venue：東京都  

researchmap

Language：Japanese   Presentation type：Oral presentation (general)  

researchmap

Language：Japanese   Presentation type：Oral presentation (general)  

researchmap

Language：Japanese   Presentation type：Oral presentation (invited, special)  

researchmap

Language：Japanese   Presentation type：Oral presentation (invited, special)  

Venue：千葉  

researchmap

Language：Japanese   Presentation type：Oral presentation (general)  

researchmap

Language：English   Presentation type：Oral presentation (general)  

Venue：Atlanta  

researchmap

Language：Japanese   Presentation type：Oral presentation (general)  

researchmap

Language：Japanese   Presentation type：Oral presentation (general)  

researchmap

Language：Japanese   Presentation type：Oral presentation (general)  

researchmap

Language：Japanese   Presentation type：Oral presentation (general)  

researchmap

Language：Japanese   Presentation type：Oral presentation (general)  

researchmap

Language：Japanese   Presentation type：Oral presentation (general)  

researchmap

Language：English   Presentation type：Poster presentation  

researchmap

Language：English   Presentation type：Poster presentation  

Venue：Seoul,Korea  

researchmap

Language：Japanese   Presentation type：Oral presentation (general)  

researchmap

Language：Japanese   Presentation type：Oral presentation (general)  

Venue：京都  

researchmap

Language：Japanese   Presentation type：Oral presentation (general)  

researchmap

Language：Japanese   Presentation type：Oral presentation (general)  

researchmap

Language：English   Presentation type：Poster presentation  

Venue：Shanghai  

researchmap

Language：English   Presentation type：Poster presentation  

Venue：Shanghai  

researchmap

Language：English   Presentation type：Poster presentation  

Venue：Shanghai  

researchmap

Language：Japanese   Presentation type：Symposium, workshop panel (nominated)  

researchmap

Language：English   Presentation type：Poster presentation  

Venue：Hong Kong  

researchmap

Language：English   Presentation type：Poster presentation  

Venue：Hong Kong  

researchmap

Language：English   Presentation type：Poster presentation  

Venue：Hong Kong  

researchmap

Language：Japanese   Presentation type：Oral presentation (general)  

researchmap

Language：English   Presentation type：Poster presentation  

Venue：Bali Indonesia  

researchmap

Language：English   Presentation type：Poster presentation  

Venue：Bali Indonesia  

researchmap

Language：English   Presentation type：Poster presentation  

Venue：Bali Indonesia  

researchmap

Language：English   Presentation type：Poster presentation  

Venue：Bali Indonesia  

researchmap

Language：English   Presentation type：Poster presentation  

Venue：Bali,indonesia  

researchmap

Language：English   Presentation type：Poster presentation  

Venue：Bali,indonesia  

researchmap

Language：Japanese   Presentation type：Oral presentation (general)  

Venue：新宿  

researchmap

Language：Japanese   Presentation type：Oral presentation (invited, special)  

Venue：旭川  

researchmap

Language：English   Presentation type：Poster presentation  

Venue：Kuala Lumpur  

researchmap

Language：English   Presentation type：Poster presentation  

Venue：Kuala Lumpur  

researchmap

Language：English   Presentation type：Poster presentation  

Venue：Bangkok Thailand  

researchmap

Language：English   Presentation type：Poster presentation  

Venue：Bangkok Thailand  

researchmap

Language：English   Presentation type：Poster presentation  

researchmap